+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
50 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
M

Actively Recruiting

Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.

Age: 18Years +All GendersPhase 2
64 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as an add-on treatment for adolescents and adults with Type 2 asthma who are at risk of flare-ups. The study compares depemokimab plus standard care with a placebo plus standard care to assess the effect on asthma exacerbations and other health outcomes. This Phase 3b4 trial is designed to understand how early intervention with depemokimab impacts lung function, asthma control, and safety over up to 156 weeks. Participants are randomly assigned to receive either depemokimab or a placebo, both alongside their usual asthma treatment. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. Treatment and assessments occur over about three years with regular monitoring of lung function and asthma symptoms. The trial includes a detailed evaluation of quality of life and asthma control scores at baseline and after two years. Participants will be involved in regular visits for lung function tests and questionnaires about their asthma control and quality of life. Researchers will track the annual rate of significant asthma exacerbations, improvements in clinical remission, and changes in lung function. Safety and adherence to treatment are also monitored throughout the study. The entire participation can last up to 156 weeks, with ongoing assessments to evaluate how the study drug affects participants asthma.

Age: 12Years +All GendersPhase 3
17 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
E

Actively Recruiting

Researchers are evaluating ALKS 2680 tablets in adults with Narcolepsy Type 1 NT1 to measure reductions in daytime sleepiness, sudden muscle tone loss cataplexy, and overall disease symptoms. This phase 3 clinical trial compares the effects of ALKS 2680 with placebo tablets to assess their impact on these key aspects of NT1. Participants are randomly assigned to one of three groups a placebo group or one of two different dose groups of ALKS 2680 tablets. All participants take their assigned oral tablets daily for 12 weeks. The study uses a triple-blind design, meaning that participants, investigators, and others involved do not know which treatment is being given. During the 12-week treatment, participants will be monitored for changes in sleep latency using the Maintenance of Wakefulness Test, daytime sleepiness via the Epworth Sleepiness Scale, weekly cataplexy rates, and other cognitive and fatigue assessments. Safety is tracked through the incidence of treatment-emergent adverse events up to 14 weeks. Outcome measures also include patient global impressions and narcolepsy severity scales to evaluate overall disease impact.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations
E

Actively Recruiting

Researchers are evaluating the effects of ALKS 2680 tablets on reducing daytime sleepiness and symptoms in adults diagnosed with Narcolepsy Type 2 NT2. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of three different doses of ALKS 2680 compared with placebo tablets. The study is sponsored by Alkermes, Inc. and uses a parallel design to compare outcomes. Participants are randomly assigned to receive one of three dose levels of ALKS 2680 tablets or a placebo, taken orally once daily for 12 weeks. The study includes a triple-blind approach to ensure unbiased results. The primary focus is on measuring changes in mean sleep latency using the Maintenance of Wakefulness Test MWT from baseline through Week 12. Secondary outcome measures include assessments of sleepiness, cognitive complaints, fatigue, and global impression scales. Throughout the 12-week treatment, participants will undergo various evaluations such as the Epworth Sleepiness Scale, Patient Global Impression-Severity scale, and Psychomotor Vigilance Task, among others. Safety is monitored by recording treatment emergent adverse events up to 14 weeks. This study includes adults aged 18 to 70 years with a confirmed diagnosis of NT2. Overall participation spans just over 12 weeks, with regular assessments to track symptom changes and treatment effects.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations

1-10 of 23

1